Barely Significant
← all phrases

“did not reach statistical significance”

111,028 sentences · 111,028 papers · 130,054 search hits before verification

In the literature

By contrast, dmPFC encoded model-based confidence estimates on both trial types: activity decreased with confidence on other-trials, but increased with confidence on self-trials, although the effect on self-trials did not reach statistical significance (c-HRF regression; confidence on other-trials, t (20) = −2.67, p = 0.015; confidence on self-trials, t (20) = 1.79, p = 0.089).
did not reach statistical significancep -value = 0.0150.3× alpha
Furthermore, overlapping with the age-stratified cohort (Corley et al., 2019), our PBMC signatures aligned strongly with the post mortem brain of the young cohort, such as in all ASD with 25 overlaps at a 76% consistency rate (hypergeometric p -value = 4.45 × 10 −15 , adjusted p -value = 5.34 × 10 −14 ), however, directional consistency across these age-stratified groups did not reach statistical significance (binomial p -value = 0.015 and adjusted p -value = 0.050) [ 28 ].
patients with GOS score 1), increased in-hospital delirium burden was significantly associated with worse GOS at discharge but did not reach statistical significance for GOS at 3, 6, and 12-months after adjusting for covariates (GOS at discharge [N = 129]: aOR, 0.03; 95% CI, 0.00–0.36; P = .015; 3 months [N = 124]: aOR, 0.90; 0.24–3.35; P = 0.880; 6 months [N = 121]: aOR, 0.70; 0.18–2.47; P = .558); 12 months [N = 110]: aOR, 0.49; 0.12–1.94; P = .312).
For all tested materials, at both the 24 h and 48 h time points, the LDH assay revealed only minor variations that did not reach statistical significance, with the exception of sample M2 at 48 h, where a statistically significant decrease was observed ( p = 0.016) ( Figure 2 A).
In the carbetocin 9.6 mg arm, trends toward numerically greater improvements in HQ-CT and CGI-C scores relative to placebo were observed but did not reach statistical significance; however, the carbetocin 3.2 mg arm demonstrated a significant improvement in HQ-CT scores (LS mean improvement vs placebo -3.14 points, p=0.016).
When the PF and PX induction regimens were combined for evaluation of the IC + CCRT group versus the CCRT + AC group, unadjusted comparisons did not reach statistical significance, but adjusted comparisons indicated a reduction in the hazards of disease progression (HR, 0.67; 95% CI, 0.48–0.93; P =0.016) and death (HR, 0.57; 95% CI, 0.39–0.86; P =0.006) ( 37 ).
The PD-1 inhibitor, pembrolizumab, combined with platinum/etoposide numerically improved mOS compared to platinum/etoposide alone in the phase III KEYNOTE-604 trial, but this did not reach statistical significance (10.8 vs 9.7 months, p = 0.0164). 37 , 38 Ipilimumab was investigated in a phase II trial with platinum/etoposide first-line but did not improve mOS compared to platinum/etoposide alone. 39 The TIGIT inhibitor, tiragolumab, was investigated in the SKYSCRAPER-02 phase II trial in combination with carboplatin/etoposide but did not produce an improvement in mPFS or mOS. 40 Additionally, ICIs have been investigated as a maintenance-only therapy.
State of the art in treatment of small cell lung cancer.
Ther Adv Med Oncol · 2025 · PMC12437200
When severe GBA variant carriers were compared to mild GBA carriers and noncarriers, a possible association was demonstrated, as the Breslow test was statistically significant and the Tarone-Ware test was at near statistical significance, while the log-rank test did not reach statistical significance ( figure ; Breslow p = 0.017, Tarone-Ware p = 0.051, log-rank p = 0.24).